Mark Cuban Cost Plus Drug Company partners with pharma company, COPD Foundation
The collaborators will improve access to Tiotropium Bromide Inhalation Powder in the U.S. for patients with COPD. (Source: mobihealthnews)
Source: mobihealthnews - September 6, 2023 Category: Information Technology Source Type: news
Lupin's arm gets UK regulator nod for COPD treatment
Global pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva, stated a press release. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 26, 2022 Category: Pharmaceuticals Source Type: news
Glenmark Pharma launches COPD treatment inhaler in UK
Drug firm Glenmark Pharma on Tuesday announced the launch of Tiotropium Bromide Dry Powder Inhaler, used in the treatment of chronic obstructive pulmonary disease (COPD), in the UK. Tiotropium DPI had a market size of USD 450 million in the EU in the 12 month period ending September 2020. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 15, 2021 Category: Pharmaceuticals Source Type: news
Spiriva (tiotropium bromide)
Title: Spiriva (tiotropium bromide)Category: MedicationsCreated: 3/3/2020 12:00:00 AMLast Editorial Review: 3/3/2020 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - March 3, 2020 Category: Drugs & Pharmacology Source Type: news
Highmark, Boehringer Ingelheim Announce Value-Based Contract for COPD...
Highmark and Boehringer Ingelheim today announced a new value-based contract for Boehringer Ingelheim’s Stiolto® Respimat® (tiotropium bromide & olodaterol) Inhalation Spray for the...(PRWeb December 12, 2019)Read the full story at https://www.prweb.com/releases/highmark_boehringer_ingelheim_announce_value_based_contract_for_copd_medication_stiolto_respimat/prweb16782338.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 12, 2019 Category: Pharmaceuticals Source Type: news
Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma
MONDAY, May 20, 2019 -- For patients with mild asthma with a low sputum eosinophil level, outcomes do not differ significantly for mometasone or tiotropium versus placebo; and budesonide-formoterol is superior to albuterol for prevention of asthma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 20, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Stiolto(R) Respimat(R) Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
Stiolto Respimat is the first in its class to have exacerbation data in the product labeling
RIDGEFIELD, Conn., Oct. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (... Biopharmaceuticals, Drug Delivery, FDA Boehringer Ingelheim, Stiolto Respimat, tiotropium, olodaterol, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2018 Category: Pharmaceuticals Source Type: news
Real-world study reports effects of Spiolto Respimat
Large European real-world study reports effects of Spiolto ® Respimat® for people living with COPD in daily clinical practice1OTIVACTO study reported improvements in both physical functioning and general condition in people living with COPD receiving Spiolto ®(tiotropium/olodaterol) Respimat® therapy14 out of 5 patients reported high satisfaction with their Respimat ® inhaler and tiotropium/olodaterol treatment overall1Data presented at European Respiratory Society International Congress 20181 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news
Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western Europe
This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the company said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2018 Category: Pharmaceuticals Source Type: news
Pulmatrix touts Ph1 data for inhaled COPD therapy
Pulmatrix (NSDQ:PULM) touted data today from a dose-ranging Phase I trial of its once-daily inhaled therapy designed for people with chronic obstructive pulmonary disease.
The company’s product is a reformulation of tiotropium bromide, the active component in Boehringer Ingelheim’s blockbuster drug, Spiriva.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix touts Ph1 data for inhaled COPD therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news
Drug safety update: Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update: Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler.
Actions (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - May 30, 2018 Category: Drugs & Pharmacology Source Type: news
Spiolto ® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine. (Source: World Pharma News)
Source: World Pharma News - May 23, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
